| Primary |
| Psoriasis |
19.1% |
| Product Used For Unknown Indication |
15.2% |
| Dermatitis Diaper |
11.2% |
| Eczema |
9.0% |
| Lichen Sclerosus |
7.2% |
| Rash |
4.3% |
| Dermatitis |
3.6% |
| Osteoporosis Postmenopausal |
3.6% |
| Dry Skin |
2.9% |
| Pruritus |
2.9% |
| Psoriatic Arthropathy |
2.9% |
| Skin Disorder |
2.9% |
| Pemphigoid |
2.5% |
| Alopecia |
2.2% |
| Atrophic Vulvovaginitis |
1.8% |
| Drug Use For Unknown Indication |
1.8% |
| Hypothyroidism |
1.8% |
| Skin Cosmetic Procedure |
1.8% |
| Vulvovaginitis |
1.8% |
| Hypertension |
1.4% |
|
| Drug Ineffective |
12.6% |
| Product Quality Issue |
10.9% |
| Incorrect Drug Administration Duration |
9.2% |
| Cellulitis |
8.4% |
| Off Label Use |
6.7% |
| Squamous Cell Carcinoma |
6.7% |
| Skin Atrophy |
5.9% |
| Cushing's Syndrome |
5.0% |
| Rash |
4.2% |
| Skin Discolouration |
4.2% |
| Overweight |
3.4% |
| Skin Infection |
3.4% |
| Cataract |
2.5% |
| Drug Administration Error |
2.5% |
| Overdose |
2.5% |
| Pruritus |
2.5% |
| Skin Candida |
2.5% |
| Vulvovaginal Erythema |
2.5% |
| Weight Increased |
2.5% |
| Alopecia |
1.7% |
|
| Secondary |
| Product Used For Unknown Indication |
20.7% |
| Pyoderma Gangrenosum |
10.5% |
| Pruritus |
9.1% |
| Eczema |
7.3% |
| Psoriasis |
6.5% |
| Dermatitis Atopic |
6.2% |
| Pemphigoid |
6.2% |
| Hypertension |
5.1% |
| Eczema Infantile |
3.3% |
| Vitiligo |
3.3% |
| Alopecia |
2.9% |
| Hypothyroidism |
2.5% |
| Alopecia Areata |
2.2% |
| Atrophic Vulvovaginitis |
2.2% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
2.2% |
| Type 2 Diabetes Mellitus |
2.2% |
| Vulvovaginal Discomfort |
2.2% |
| Dermatitis Exfoliative |
1.8% |
| Prophylaxis |
1.8% |
| Rash |
1.8% |
|
| Off Label Use |
13.3% |
| Cushing's Syndrome |
11.1% |
| Condition Aggravated |
6.7% |
| Drug Ineffective |
6.7% |
| Growth Retardation |
6.7% |
| Abdominal Pain |
4.4% |
| Decreased Appetite |
4.4% |
| Drug Eruption |
4.4% |
| Pain |
4.4% |
| Product Substitution Issue |
4.4% |
| Skin Striae |
4.4% |
| Streptococcus Test Positive |
4.4% |
| Vitiligo |
4.4% |
| Vomiting |
4.4% |
| Wound Dehiscence |
4.4% |
| Acarodermatitis |
2.2% |
| Acute Febrile Neutrophilic Dermatosis |
2.2% |
| Adrenal Suppression |
2.2% |
| Amyotrophy |
2.2% |
| Application Site Pain |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
22.4% |
| Psoriasis |
20.1% |
| Hepatitis C |
9.6% |
| Drug Use For Unknown Indication |
7.6% |
| Hypertension |
5.5% |
| Pain |
4.7% |
| Psoriatic Arthropathy |
4.5% |
| Rheumatoid Arthritis |
3.6% |
| Prophylaxis |
3.0% |
| Diabetes Mellitus |
2.4% |
| Gastrooesophageal Reflux Disease |
2.3% |
| Depression |
1.9% |
| Rash |
1.8% |
| Anxiety |
1.8% |
| Eczema |
1.7% |
| Insomnia |
1.6% |
| Constipation |
1.6% |
| Graft Versus Host Disease |
1.4% |
| Nausea |
1.4% |
| Asthma |
1.1% |
|
| Psoriasis |
11.7% |
| Vomiting |
9.0% |
| Weight Decreased |
9.0% |
| Weight Increased |
8.0% |
| Rash |
6.5% |
| Breast Cancer |
4.9% |
| Drug Ineffective |
4.6% |
| Myocardial Infarction |
4.6% |
| Pyrexia |
4.6% |
| Loss Of Consciousness |
4.0% |
| Death |
3.7% |
| Oedema Peripheral |
3.7% |
| Skin Exfoliation |
3.7% |
| Anaemia |
3.4% |
| Cellulitis |
3.1% |
| Deep Vein Thrombosis |
3.1% |
| Nausea |
3.1% |
| Pulmonary Embolism |
3.1% |
| Toxic Skin Eruption |
3.1% |
| Type 1 Diabetes Mellitus |
3.1% |
|
